PYRGF vs. CRVS, TRVI, CMPS, AQST, GOSS, CADL, ATYR, IMMP, OLMA, and KRRO
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), COMPASS Pathways (CMPS), Aquestive Therapeutics (AQST), Gossamer Bio (GOSS), Candel Therapeutics (CADL), Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs.
Corvus Pharmaceuticals (NASDAQ:CRVS) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
Corvus Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.
46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
PyroGenesis Canada has higher revenue and earnings than Corvus Pharmaceuticals. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Corvus Pharmaceuticals currently has a consensus price target of $12.38, suggesting a potential upside of 195.35%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Corvus Pharmaceuticals is more favorable than PyroGenesis Canada.
Corvus Pharmaceuticals received 291 more outperform votes than PyroGenesis Canada when rated by MarketBeat users.
In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 1 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat PyroGenesis Canada's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.
Corvus Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Summary
Corvus Pharmaceuticals beats PyroGenesis Canada on 11 of the 16 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 2/22/2025 by MarketBeat.com Staff
